EASD 2017: Exenatide Did Not Reduce MACE in Patients With Type 2 Diabetes Though It Did Reduce All-Cause Mortality - EXSCEL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Only registered members have full access to PracticeUpdate content.